Factor XIa Inhibitor Shows No Benefit After Acute Coronary Syndrome
(MedPage Today) -- An investigational factor XIa inhibitor did not reduce the risk of recurrent cardiovascular (CV) events in patients with a recent acute coronary syndrome (ACS) event on top of antiplatelet therapy, although there was no increase...
The LIBREXIA ACS trial, presented at the European Society of Cardiology Congress in Munich, found that an investigational factor XIa inhibitor, milvexian, did not reduce the risk of recurrent cardiovascular events in patients with acute coronary syndrome (ACS) on antiplatelet therapy. After a median follow-up of 12.2 months, 5.4% of patients in the milvexian group and 5.1% in the placebo group experienced one of the following events: cardiovascular death, myocardial infarction, or ischemic stroke.
The drug was halted early due to lack of efficacy, as the study's primary outcome was not met. Despite this, milvexian did not increase the risk of major bleeding, a safety outcome of concern. The trial involved 14,194 patients across 900 international sites, with a high incidence of major adverse cardiovascular events, emphasizing the need for safer anticoagulant options.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
